FDA AI/ML SaMD Action Plan

FDA AI/ML SaMD Action Plan — Software as a Medical Device
United States · FDA AI/ML SaMD Action Plan (Jan. 12, 2021)

Status
In effect
Took effect
January 12, 2021
Applies to
Manufacturers of AI/ML SaMD
Enforced by
FDA / CDRH

FDA's 5-part roadmap for regulating AI/ML-based Software as a Medical Device, including a proposed Predetermined Change Control Plan framework that lets developers update models without full FDA re-review.

Who is protected: Patients receiving care that involves AI/ML medical devices

Legal detail

FDA AI/ML SaMD Action Plan (Jan. 12, 2021): articulates 5 actions — (1) tailored regulatory framework with PCCP, (2) GMLP, (3) patient-centered transparency, (4) regulatory science methods for bias and robustness, (5) real-world performance monitoring. Foundation for FDA's AI/ML SaMD reviews and the 2024 Transparency Guiding Principles.

Key facts

JurisdictionUnited States
LevelFederal
StrengthModerate
EnactedJanuary 12, 2021
CitationFDA AI/ML SaMD Action Plan (Jan. 12, 2021)
Private right of actionNo, agency enforcement only
PenaltiesFDCA enforcement: warning letters, recalls, civil penalties
Topicshealthcare AI · automated decision-making
Agency pageFDA AI/ML SaMD Action Plan (PDF)

More AI rules in United States

Related healthcare AI rules elsewhere

See something wrong or out of date? Submit a correction. Every entry must carry a verifiable source.